Bicycle Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Bicycle Therapeutics (NASDAQ: BCYC) has announced the approval of inducement awards for 18 new employees by its Board's Compensation Committee. The awards, granted on February 3, 2025, consist of non-qualified share options to purchase a total of 117,300 ordinary shares under the company's 2024 Inducement Plan.
The options have an exercise price of $13.39 per share, matching Bicycle's closing price on January 31, 2025. These options will vest over a four-year period, with 25% vesting after one year and the remaining shares vesting monthly over the subsequent 36 months, contingent on continued employment. The grants were made in accordance with Nasdaq Listing Rule 5635(c)(4) as inducement material for employment.
Bicycle Therapeutics (NASDAQ: BCYC) ha annunciato l'approvazione di premi di incentivo per 18 nuovi dipendenti da parte del Comitato per la Compensazione del Consiglio. I premi, concessi il 3 febbraio 2025, consistono in opzioni su azioni non qualificate per l'acquisto di un totale di 117.300 azioni ordinarie nell'ambito del Piano di Incentivo 2024 dell'azienda.
Le opzioni hanno un prezzo di esercizio di $ 13,39 per azione, corrispondente al prezzo di chiusura di Bicycle del 31 gennaio 2025. Queste opzioni matureranno nel corso di un periodo di quattro anni, con il 25% che matura dopo un anno e le rimanenti azioni che maturano mensilmente nei successivi 36 mesi, a condizione di un'occupazione continuativa. I premi sono stati concessi in conformità con la Regola di Quotazione Nasdaq 5635(c)(4) come materiale di incentivo per l'occupazione.
Bicycle Therapeutics (NASDAQ: BCYC) ha anunciado la aprobación de premios de incentivo para 18 nuevos empleados por parte del Comité de Compensación de su Junta. Los premios, otorgados el 3 de febrero de 2025, consisten en opciones de acciones no calificadas para adquirir un total de 117,300 acciones ordinarias bajo el Plan de Incentivo 2024 de la compañía.
Las opciones tienen un precio de ejercicio de $13.39 por acción, coincidiendo con el precio de cierre de Bicycle del 31 de enero de 2025. Estas opciones se consolidarán durante un período de cuatro años, con un 25% que se consolidará después de un año y las acciones restantes consolidándose mensualmente durante los siguientes 36 meses, sujeto a la continuación del empleo. Las concesiones se realizaron de acuerdo con la Regla de Cotización Nasdaq 5635(c)(4) como material de incentivo para el empleo.
바이시클 테라퓨틱스 (NASDAQ: BCYC)는 보상위원회에서 18명의 신규 직원에 대한 유인 보상 승인을 발표했습니다. 이 보상은 2025년 2월 3일에 수여되었으며, 회사의 2024년 유인 계획에 따라 총 117,300주 보통주를 구매할 수 있는 비자격 주식옵션으로 구성됩니다.
이 옵션의 행사가는 주당 $13.39로, 2025년 1월 31일 바이시클의 종가와 일치합니다. 이 옵션은 4년 동안 분할되어 1년 후 25%가 확정되며, 나머지 주식은 향후 36개월 동안 매달 확정됩니다. 이는 지속적인 고용 조건에 따릅니다. 이 보상은 고용 유인을 위한 자료로서 나스닥 상장 규칙 5635(c)(4)에 따라 이루어졌습니다.
Bicycle Therapeutics (NASDAQ: BCYC) a annoncé l'approbation de récompenses d'incitation pour 18 nouveaux employés par son comité de rémunération. Les récompenses, accordées le 3 février 2025, consistent en des options d'achat d'actions non qualifiées pour l'acquisition d'un total de 117,300 actions ordinaires dans le cadre du Plan d'Incitation 2024 de la société.
Les options ont un prix d'exercice de 13,39 $ par action, correspondant au prix de clôture de Bicycle du 31 janvier 2025. Ces options seront acquises sur une période de quatre ans, avec 25 % qui seront acquis après un an et les actions restantes acquises mensuellement au cours des 36 mois suivants, sous réserve d'un emploi continu. Les attributions ont été effectuées conformément à la règle de cotation Nasdaq 5635(c)(4) en tant que matériel d'incitation à l'emploi.
Bicycle Therapeutics (NASDAQ: BCYC) hat die Genehmigung von Anreizprämien für 18 neue Mitarbeiter durch den Vergütungsausschuss des Unternehmens bekannt gegeben. Die Prämien, die am 3. Februar 2025 gewährt wurden, bestehen aus nicht qualifizierten Aktienoptionsscheinen zum Kauf von insgesamt 117.300 Stammaktien im Rahmen des Unternehmensplans von 2024.
Die Optionen haben einen Ausübungspreis von 13,39 $ pro Aktie, der dem Schlusskurs von Bicycle am 31. Januar 2025 entspricht. Diese Optionen vesten über einen Zeitraum von vier Jahren, wobei 25% nach einem Jahr vesten und die verbleibenden Aktien monatlich in den folgenden 36 Monaten vesten, abhängig von einer fortgesetzten Beschäftigung. Die Zuteilungen wurden gemäß der Nasdaq-Listungsregel 5635(c)(4) als Anreizmaterial für die Beschäftigung vorgenommen.
- Company demonstrates growth with hiring of 18 new employees
- Implementation of employee retention strategy through stock options
- Potential future dilution from 117,300 new share options
Each option has an exercise price equal to
About Bicycle Therapeutics
Bicycle Therapeutics is a clinical-stage pharmaceutical company developing a novel class of medicines, referred to as Bicycle® molecules, for diseases that are underserved by existing therapeutics. Bicycle molecules are fully synthetic short peptides constrained with small molecule scaffolds to form two loops that stabilize their structural geometry. This constraint facilitates target binding with high affinity and selectivity, making Bicycle molecules attractive candidates for drug development. The company is evaluating zelenectide pevedotin (formerly BT8009), a Bicycle® Toxin Conjugate (BTC®) targeting Nectin-4, a well-validated tumor antigen; BT5528, a BTC molecule targeting EphA2, a historically undruggable target; and BT7480, a Bicycle Tumor-Targeted Immune Cell Agonist® (Bicycle TICA®) targeting Nectin-4 and agonizing CD137, in company-sponsored clinical trials. Additionally, the company is developing Bicycle® Radionuclide Conjugates (BRC®) for radiopharmaceutical use and, through various partnerships, is exploring the use of Bicycle® technology to develop therapies for diseases beyond oncology.
Bicycle Therapeutics is headquartered in
View source version on businesswire.com: https://www.businesswire.com/news/home/20250203671729/en/
Investors:
Stephanie Yao
SVP, Investor Relations and Corporate Communications
stephanie.yao@bicycletx.com
857-523-8544
Matthew DeYoung
Argot Partners
ir@bicycletx.com
212-600-1902
Media:
Jim O’Connell
Weber Shandwick
media@bicycletx.com
312-988-2343
Source: Bicycle Therapeutics plc
FAQ
How many shares were granted in BCYC's February 2025 inducement awards?
What is the exercise price for BCYC's February 2025 inducement stock options?
What is the vesting schedule for BCYC's 2025 inducement stock options?
How many new employees received BCYC inducement awards in February 2025?
